Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143223 | 0.85 | GAA (0.46) | GAASMN1; SMN2HTTEGLN1MAPT | |
| SCHEMBL10893317 | 0.83 | GAA (0.47) | GAASMN1; SMN2HTTEGLN1MAPT | |
| SCHEMBL9150632 | 0.82 | GAA (0.50) | GAASMN1; SMN2HTTEGLN1MAPT | |
| SCHEMBL29201470 | 0.82 | EGLN1 (0.55) | GAASMN1; SMN2HTTEGLN1MAPT | |
| SCHEMBL26007510 | 0.80 | GAA (0.49) | GAASMN1; SMN2HTTEGLN1MAPT | |
| SCHEMBL19255014 | 0.80 | GAA (0.50) | GAASMN1; SMN2HTTEGLN1MAPT | |
| SCHEMBL23988162 | 0.79 | EGLN1 (0.52) | GAASMN1; SMN2HTTEGLN1MAPT | |
| SCHEMBL23139788 | 0.78 | MAPT (0.46) | GAASMN1; SMN2HTTEGLN1MAPT | |
| SCHEMBL8344696 | 0.78 | GAA (0.47) | GAASMN1; SMN2HTTEGLN1MAPT | |
| SCHEMBL15659309 | 0.77 | GAA (0.46) | GAASMN1; SMN2HTTEGLN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306166-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306166-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | H. LUNDBECK A/S (DK) | 2023-12-26 | — | — | US | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3557998-B1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-111556871-B | 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | H. LUNDBECK A/S (DK) | 2023-04-25 | — | — | US | disclosed |
| US-11542233-B2 | Compounds, compositions and methods of use | AQUINNAH PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2018-01-04 | — | — | US | disclosed |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2018-01-04 | — | — | US | disclosed |
| WO-2016127859-A1 | COMPOUNDS AS HEPATITIS C INHIBITORS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-18 | — | — | WO | disclosed |
| WO-2013093508-A2 | WNT PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013093508-A2 | WNT PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2013-06-27 | — | — | WO | disclosed |
| US-8318754-B2 | Pyrimidinecarboxamide derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100152214-A1 | NOVEL PYRIMIDINECARBOXAMIDE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7687509-B2 | Pyrimidinecarboxamide derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090035324-A1 | NOVEL PYRIMIDINECARBOXAMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009009531-A2 | PYRIMIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS | CONCERT PHARMACEUTICALS INC. (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542233-B2 | Compounds, compositions and methods of use | FUS, TFEB, CLN6 | GAA 322/4885SMN1; SMN2 35/4885HTT 56/4885 |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | GAA 322/4885SMN1; SMN2 35/4885HTT 56/4885 |
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | PDE3B, PDE1B, PDE12 | GAA 334/4885SMN1; SMN2 108/4885HTT 551/4885 |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | PDE1B, PDE3B, PDE1A | GAA 702/4885SMN1; SMN2 2582/4885HTT 2881/4885 |
| US-20090035324-A1 | NOVEL PYRIMIDINECARBOXAMIDE DERIVATIVES | TYMP, PNP, DPYD | GAA 1104/4885SMN1; SMN2 3655/4885HTT 4628/4885 |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | PDE3A, PDE5A, PDE12 | GAA 322/4885SMN1; SMN2 422/4885HTT 1321/4885 |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | GAA 728/4885SMN1; SMN2 1592/4885HTT 584/4885 |
| US-20100152214-A1 | NOVEL PYRIMIDINECARBOXAMIDE DERIVATIVES | TYMP, PNP, DPYD | GAA 1104/4885SMN1; SMN2 3655/4885HTT 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.